Neoplasms, Unknown Primary Clinical Trial
Official title:
A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site
In this phase II trial, we will evaluate the feasibility and efficacy of the oxaliplatin/capecitabine combination in patients who have had one previous chemotherapy regimen for the treatment of carcinoma of unknown primary site. Patients who are relapsed after a previous response to treatment will be eligible, as well as those who were refractory to first-line therapy.
All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 PO BID was administered on days 1-14 of each cycle. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04025970 -
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
|
||
| Completed |
NCT00193596 -
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
|
Phase 3 | |
| Completed |
NCT02628379 -
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
|
||
| Completed |
NCT01202786 -
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
|
N/A | |
| Completed |
NCT01540058 -
Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP
|
Phase 3 | |
| Not yet recruiting |
NCT00894569 -
Paclitaxel/Carboplatin With or Without Cetuximab in CUP
|
Phase 2 | |
| Completed |
NCT00193622 -
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
|
Phase 2 |